‌

US Patent 12077570 Anti-VEGF protein compositions and methods for producing the same

Patent 12077570 was granted and assigned to Regeneron Pharmaceuticals on September, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Regeneron Pharmaceuticals

0

Current Assignee

Regeneron Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Erica Pyles0

Thomas Daly0

Nisha Palackal0

Ankit Vartak0

Andrew Tustian0

Date of Patent

September 3, 2024

0

Patent Application Number

181185580

Date Filed

March 7, 2023

0

Patent Citations

US Patent 7279159 VEGF inhibitor polypeptides

0

US Patent 7303746 Methods of treating eye disorders with modified chimeric polypeptides

0

US Patent 7303747 Use of VEGF inhibitors for treatment of eye disorders

0

US Patent 7306799 Use of VEGF inhibitors for treatment of eye disorders

0

US Patent 7332303 Product quality enhancement in mammalian cell culture processes for protein production

0

US Patent 7374757 Modified chimeric polypeptides with improved pharmacokinetic properties

0

US Patent 7374758 Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereof

0

US Patent 7396664 VEGF-binding fusion proteins and nucleic acids encoding the same

0

...

Patent Primary Examiner

Michael D Burkhart

0

Patent abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12077570 Anti-VEGF protein compositions and methods for producing the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.